Neogen (NEOG) Q2 2026 earnings review
Transformation Takes Hold: Guidance Raised as Margins Snap Back
Neogen's Q2 marked a pivotal stabilization point under new CEO Mike Nassif. After a shaky Q1, the company delivered a 'clean' quarter with significant sequential improvements. While reported revenue fell 2.8% YoY due to divestitures, Core Revenue returned to growth (+2.9%). The standout metric was Adjusted EBITDA margin, which surged 470 basis points sequentially to 21.7%, driven by aggressive cost actions and volume leverage. Consequently, management raised full-year FY26 revenue and EBITDA guidance, signaling that the operational trough is likely behind them.
🐂 Bull Case
Core revenue growth improved to +2.9% (vs +0.3% in Q1), led by a resilient Food Safety segment (+4.1%). The business is showing organic traction despite macro headwinds.
Adjusted EBITDA margin rebounded sharply to 21.7% from 17.0% in Q1. The raised FY26 guidance ($175M EBITDA) implies maintained discipline in H2.
🐻 Bear Case
While Food Safety grows, Animal Safety core revenue remains flat (+0.1%). Weakness in veterinary instruments (needles/syringes) continues to drag on the segment.
Despite adjusted improvements, Neogen posted a GAAP Net Loss of $15.9M. Interest expense ($14.3M) and integration costs continue to consume operating profit.
⚖️ Verdict: 🟢
Bullish. The sequential improvement in margins and the immediate guidance raise suggest the new leadership's 'strategic transformation' is working faster than expected. Execution risk remains on the Petrifilm integration, but the financial floor has been established.
Key Themes
Sequential Margin Explosion
Accelerating. Adjusted EBITDA margin expanded 470 bps sequentially to 21.7%. This breaks a trend of margin compression seen in late FY25 and Q1 FY26. Drivers include lower operating expenses (Sales & Marketing -9% YoY) and better overhead absorption, despite gross margin pressure from tariffs.
Food Safety Resilience
Stable/Accelerating. The Food Safety segment (74% of revenue) grew core revenue 4.1%, offsetting divestiture impacts. Strength was noted in Indicator Testing, Culture Media, and Pathogen Detection. This segment remains the primary investment thesis engine.
Integration & Manufacturing Costs
Ongoing. Gross margin fell to 47.5% (from 49.0% prior year), driven by tariff costs, inventory write-offs, and negative mix. Specifically, the company cited 'Petrifilm manufacturing transition' as on track but still a cost center. Until the 3M integration is fully lapsed, gross margin upside is capped.
Animal Safety Headwinds
Decelerating. Reported revenue collapsed 11.8% due to divestitures, but even Core growth was anemic at +0.1% (vs +5.8% in Q1). The company flagged declines in 'needles and syringes' and timing issues in Life Sciences. This segment lacks the momentum of Food Safety.
Strategic Transformation Phase 1
New. CEO Mike Nassif explicitly labeled this 'Phase 1' of a strategic transformation focusing on stabilizing the core. The immediate raise in guidance suggests early validation of resource allocation changes and commercial leadership hires.
Other KPIs
Accelerating from +0.3% in Q1. This metric isolates organic health by excluding the noise from the Cleaners & Disinfectants divestiture and currency fluctuations.
Reversing trend. While down YoY (-5%) due to divestitures, it is up sharply (+37%) sequentially from Q1's $35.5M, demonstrating operating leverage is returning.
Stable. Cash ($145M) vs Total Debt ($800M). The company maintains committed borrowing capacity of $201.5M, but interest expense (~$14M/quarter) remains a significant drag on GAAP earnings.
Guidance
Accelerating / Raised. Previous guidance was $820-$840M. The new range implies H2 revenue of ~$411-$421M, consistent with the Q2 run rate. This removes the fear of a second-half drop-off.
Stable / Raised. Previous guidance was $165-$175M. The midpoint has effectively moved up. Implies H2 EBITDA of ~$91M (avg ~$45.5M/quarter), slightly below Q2's $48.7M, likely baking in some conservatism or integration spend timing.
Key Questions
Gross Margin Bridge
Gross margins compressed 150bps YoY despite the divestiture of lower-margin businesses. How much of this is structural tariff pressure vs. temporary Petrifilm integration costs?
Animal Safety Turnaround
Core growth in Animal Safety stalled to 0.1%. Is the decline in veterinary instruments a market share issue or a destocking event, and when should we expect a return to mid-single-digit growth?
Free Cash Flow & Deleveraging
With $800M in debt and $14M in quarterly interest expense, what is the target net leverage ratio for FY26 end, and will FCF generation accelerate in H2?
Petrifilm Manufacturing Risk
Management noted the manufacturing transition is 'on track.' Can you quantify the remaining duplicate costs expected in H2 and confirm the 'go-live' date for independent production?